ASSOCIATE PROF. DR. PANG YONG KEK
Department of Medicine
Faculty of Medicineykpang@um.edu.my
|Sorry, no accessible project found|
|This information is generated from Research Grant Management System|
Epidermal growth factor receptor mutation in newly diagnosed lung adenocarcinoma
Close contact investigation of TB in high-burden, low- and middle-income countries
EGFR mutations in Asian patients with advanced lung adenocarcinoma.
Tuberculosis (TB)-associated immune reconstitution inflammatory syndrome in TB-HIV co-infected patients in Malaysia: prevalence, risk factors, and treatment outcomes.
Drugs and The Respiratory System
Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)